A Phase 2 interventional study of TransCon CNP and Placebo for TransCon CNP in Achondroplasia, sponsored by Ascendis Pharma A/S. Completed at 15 sites in 8 countries. Open to participants aged 2 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Ascendis Pharma A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Achondroplasia with a site in United States — 8 open to participants now, 11 under way, 3 of them phase 3. Achondroplasia · United States.
Among the 29 studies in Achondroplasia with a site in United States, this one is the 16th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2020, is one of 12 in phase 2, and was the 15th registered.
47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.
Browse Achondroplasia studies →8 of the 29 studies in Achondroplasia with a site in United States are open now. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States, Australia, Canada and 6 more countries
Ages 2–17
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 4 more countries
Ages 0 yrs–32 mo
Tyra Biosciences, Inc · Sites in United States, Australia, Canada and 5 more countries
Ages 3–10
Ascendis Pharma A/S · Sites in United States, Australia, Austria and 12 more countries
Ages 0–2
BioMarin Pharmaceutical · Sites in United States
Ages 0 mo–18 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 2 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 15 · Phase 3 6
First in 1996; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 74 across 28 interventional studies indexed under Achondroplasia.
Median enrollment 76 across the 20 interventional studies, 271 across the 9 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 29 have an industry lead sponsor. The 9 most frequent:
Ascendis Pharma A/S is the lead sponsor of 17 studies on the registry; 7 are open to participants now.
Ascendis Pharma A/S has 5 studies filed under Achondroplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Achondroplasia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10 years old, inclusive, with Achondroplasia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
findings at Screening that:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TransCon CNP 6 mcg CNP/kg delivered once weekly by subcutaneous injection.
Drug: TransCon CNP
TransCon CNP 20 mcg CNP/kg delivered once weekly by subcutaneous injection.
Drug: TransCon CNP
TransCon CNP 50 mcg CNP/kg delivered once weekly by subcutaneous injection.
Drug: TransCon CNP
TransCon CNP 100 mcg CNP/kg delivered once weekly by subcutaneous injection.
Drug: TransCon CNP
Placebo mimicking 6, 20, 50, or 100 mcg CNP/kg delivered once weekly by subcutaneous injection.
Drug: Placebo for TransCon CNP
Participants who completed the 52-week blinded treatment period continued into the 104-week open-label extension period and received treatment with TransCon CNP (navepegritide) doses escalated up to a maximum of 100 mcg/kg delivered once weekly by subcutaneous injection.
Drug: TransCon CNP
TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
Weekly subcutaneously injection of placebo.
Annualized Height Velocity (cm/Year) After 52 Weeks of Double-blind Treatment
The primary efficacy analysis compared the difference in the primary efficacy endpoint between the TransCon CNP treatment group and the pooled placebo group using an ANCOVA model with the annualized height velocity (AHV) at Week 52 as the response variable, treatment (dose groups and placebo) and sex as factors, baseline age and baseline height SDS as the covariates, and based on the Full Analysis Set.
Time frame: 52 weeks
| Milestone | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Open-Label Extension Period: TransCon CNP |
|---|---|---|---|---|---|---|
| Started | 10 | 11 | 10 | 11 | 15 | 0 |
| Completed | 10 | 11 | 10 | 11 | 15 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Open-Label Extension Period: TransCon CNP |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 57 |
| Completed | 0 | 0 | 0 | 0 | 0 | 55 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 2 |
The primary efficacy analysis compared the difference in the primary efficacy endpoint between the TransCon CNP treatment group and the pooled placebo group using an ANCOVA model with the annualized height velocity (AHV) at Week 52 as the response variable, treatment (dose groups and placebo) and sex as factors, baseline age and baseline height SDS as the covariates, and based on the Full Analysis Set.
| cm/year | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo |
|---|---|---|---|---|---|
| Annualized Height Velocity (cm/Year) After 52 Weeks of Double-blind Treatment | 4.09 (3.34 to 4.84) | 4.52 (3.82 to 5.22) | 5.16 (4.43 to 5.90) | 5.42 (4.74 to 6.11) | 4.35 (3.75 to 4.94) |
Collected over From Week 0 to Week 52 for double-blind treatment period and up to Week 156 for OLE Period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TransCon CNP 6 mcg | 0/10 (0%) | 1/10 (10%) | 9/10 (90%) |
| TransCon CNP 20 mcg | 0/11 (0%) | 0/11 (0%) | 11/11 (100%) |
| TransCon CNP 50 mcg | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| TransCon CNP 100 mcg | 0/11 (0%) | 0/11 (0%) | 10/11 (90.9%) |
| Placebo | 0/15 (0%) | 0/15 (0%) | 14/15 (93.3%) |
| Open-Label Extension Period: TransCon CNP | 0/57 (0%) | 2/57 (3.5%) | 57/57 (100%) |
| Event | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Open-Label Extension Period: TransCon CNP |
|---|---|---|---|---|---|---|
| Febrile ConvulsionNervous system disorders | 0/10 | 0/11 | 1/10 | 0/11 | 0/15 | 0/57 |
| Viral infectionInfections and infestations | 1/10 | 0/11 | 0/10 | 0/11 | 0/15 | 0/57 |
| InfluenzaInfections and infestations | 1/10 | 0/11 | 0/10 | 0/11 | 0/15 | 1/57 |
| Obstructive sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 0/10 | 0/11 | 0/10 | 0/11 | 0/15 | 1/57 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 0/10 | 0/11 | 0/10 | 0/11 | 0/15 | 1/57 |
| Event | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Open-Label Extension Period: TransCon CNP |
|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/10 | 1/11 | 5/10 | 0/11 | 2/15 | 14/57 |
| NasopharyngitisInfections and infestations | 1/10 | 0/11 | 5/10 | 2/11 | 1/15 | 20/57 |
| PyrexiaGeneral disorders | 1/10 | 4/11 | 2/10 | 2/11 | 5/15 | 23/57 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/10 | 3/11 | 4/10 | 2/11 | 3/15 | 21/57 |
| COVID-19Infections and infestations | 0/10 | 1/11 | 1/10 | 3/11 | 1/15 | 20/57 |
| HeadacheNervous system disorders | 0/10 | 1/11 | 3/10 | 2/11 | 2/15 | 17/57 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/10 | 1/11 | 3/10 | 3/11 | 1/15 | 7/57 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/10 | 0/11 | 3/10 | 1/11 | 1/15 | 9/57 |
| GastroenteritisInfections and infestations | 0/10 | 2/11 | 3/10 | 1/11 | 2/15 | 10/57 |
| Respiratory tract infectionInfections and infestations | 0/10 | 0/11 | 3/10 | 0/11 | 0/15 | 0/57 |
| Age, Continuous(years) | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 6.52 ± 2.593 | 6.29 ± 2.896 | 5.20 ± 2.991 | 5.79 ± 2.613 | 5.89 ± 3.109 | 5.94 ± 2.800 |
| Sex: Female, Male(Participants) | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 7 | 3 | 3 | 6 | 5 | 24 |
| Male | 3 | 8 | 7 | 5 | 10 | 33 |
| Ethnicity (NIH/OMB)(Participants) | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 2 | 1 | 6 |
| Not Hispanic or Latino | 9 | 11 | 6 | 9 | 14 | 49 |
| Unknown or Not Reported | 0 | 0 | 2 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 1 | 0 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 1 | 1 | 2 |
| White | 8 | 10 | 8 | 10 | 12 | 48 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Height(cm) | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 90.63 ± 8.973 | 92.29 ± 12.103 | 86.61 ± 12.967 | 89.23 ± 12.822 | 90.85 ± 14.920 | 90.03 ± 12.434 |
| Height SDS(standard deviation score) | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | -5.45 ± 1.046 | -4.87 ± 0.673 | -4.85 ± 0.801 | -4.92 ± 0.829 | -4.85 ± 0.958 | -4.97 ± 0.873 |
| Weight(kg) | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 17.49 ± 3.677 | 19.67 ± 6.602 | 15.67 ± 4.399 | 17.03 ± 4.699 | 17.99 ± 5.542 | 17.64 ± 5.129 |
| Body Mass Index (BMI)(kg/m^2) | TransCon CNP 6 mcg | TransCon CNP 20 mcg | TransCon CNP 50 mcg | TransCon CNP 100 mcg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 21.10 ± 1.664 | 22.52 ± 2.599 | 20.61 ± 1.496 | 21.11 ± 1.612 | 21.39 ± 1.853 | 21.36 ± 1.930 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2020 to primary completion in Sep 2022, 27 months.
Results were first posted in Mar 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Navepegritide
Ascendis Pharma A/S